Welcome
Support Centre
19 November 2008 
ISRCTN Register - International Standard Randomized Controlled Trial Number
Trial registration
Unique identification scheme
International databases
home  |   my details  |   ISRCTN Register  |   mRCT  |   UKCTG  |   links  |   information  |   press
Find trials
ISRCTN Register
tips on searching

Registration
New application
Updating record

Information
introduction
governing board
ISRCTN FAQs
data set
letter of agreement
request information
guidance notes

[ Print-friendly version ]
Unilateral randomised double-blind placebo-controlled continuation of existing open-labelled intraputaminal GDNF (glial derived neurotrophic factor) infusion study for 6-months in subjects with idiopathic Parkinsons disease
ISRCTN ISRCTN67335687
ClinicalTrials.gov identifier
Public title Unilateral randomised double-blind placebo-controlled continuation of existing open-labelled intraputaminal GDNF (glial derived neurotrophic factor) infusion study for 6-months in subjects with idiopathic Parkinsons disease
Scientific title
Acronym N/A
Serial number at source N0234120876
Study hypothesis The open-labelled trial has to date established the long term safety and therapeutic benefits of chronic intraputaminal GDNF infusion in the five patients with Parkinson's disease. This trial aims to assess the clinical effect of unilateral randomised double-blinded placebo controlled cessation of GDNF for 6-months. Unilateral cessation of GDNF infusion may result in either contralateral stability or a reduction of the improved clinical state.
Ethics approval Not provided at time of registration
Study design Randomised controlled trial
Countries of recruitment United Kingdom
Disease/condition/study domain Nervous System Diseases: Parkinson's disease
Participants - inclusion criteria Five patients currently enrolled in the open labelled study.
Participants - exclusion criteria Not provided at time of registration
Anticipated start date 01/03/2003
Anticipated end date 01/10/2003
Status of trial Completed
Patient information material
Target number of participants 5
Interventions Unilateral randomised double-blind placebo controlled study.
Primary outcome measure(s) Unified Parkinson's disease Rating Scores (UPDRS) - total and lateralised scores. Timed motor tests. Patient diary assessments. Quality of life measures - PDQ-39 and SF-36. Change in medication requirement. 18F-dopa positron emission tomography (PET) changes. Safety assessments.
Secondary outcome measure(s) Not provided at time of registration
Sources of funding North Bristol NHS Trust
Trial website
Publications
Contact name Dr  P  Heywood
  Address Department of Neurology
North Bristol NHS Trust
Frenchay Hospital
Frenchay
  City/town Bristol
  Zip/Postcode BS16 1ND
  Country United Kingdom
  Tel +44 0117 970 1212
  Fax +44 0117 975 3824
  Email research@southmead.swest.nhs.uk
Sponsor Record provided by the NHS Trusts Clinical Trials Register - Department of Health (UK)
  Address The Department of Health
Richmond House
79 Whitehall
  City/town London
  Zip/Postcode SW1A 2NL
  Country United Kingdom
  Tel +44 (0)20 7307 2622
  Fax +44 (0)20 7307 2623
  Email dhmail@doh.gsi.org.uk
  Sponsor website: http://www.doh.gov.uk
Date applied 12/09/2003
Last edited 21/11/2005
Date ISRCTN assigned 12/09/2003
Submit your trial protocol Top studies in medical research Submit to Trials journal
© ISRCTN


BioMed Central